Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Sale of Stock, Consideration Received on Transaction

Cartesian Therapeutics, Inc. Sale of Stock, Consideration Received on Transaction

Cartesian Therapeutics, Inc. (RNAC) reported Sale of Stock, Consideration Received on Transaction of $30.90 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-08.

Discontinued › Notes › Equity

us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2019-11-08

  • Cartesian Therapeutics, Inc. sale of stock, consideration received on transaction for the quarter ending 2019-09-30 was $0.00.
  • Cartesian Therapeutics, Inc. sale of stock, consideration received on transaction for the quarter ending 2019-06-30 was $0.00.
  • Cartesian Therapeutics, Inc. sale of stock, consideration received on transaction for the quarter ending 2019-03-31 was $30.90M.
Period endSale of Stock, Consideration Received on Transaction 3 monthSale of Stock, Consideration Received on Transaction 6 monthSale of Stock, Consideration Received on Transaction 9 month
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$0.00
derived: sum of 2 quarters · filed 2019-11-08
$30.90M
10-Q · filed 2019-11-08
2019-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$30.90M
10-Q · filed 2019-08-08
2019-03-31$30.90M
10-Q · filed 2019-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23